Phase II Trial of Pembrolizumab in Hormone Receptor-positive, hyperMUTATted Metastatic Breast Cancer Identified by Whole exOme sequeNcing ('MUTATION2')
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms MUTATION2
- 07 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.
- 09 Jan 2019 Planned initiation date changed from 1 May 2018 to 1 Jan 2019.
- 12 Apr 2018 New trial record